Ads
related to: stomach polyps caused by ppi or h2 acid reflux treatment
Search results
Results From The WOW.Com Content Network
The proton pump is the terminal stage in gastric acid secretion, being directly responsible for secreting H + ions into the gastric lumen, making it an ideal target for inhibiting acid secretion. [ citation needed ] Because the H,K-ATPase is the final step of acid secretion, an inhibitor of this enzyme is more effective than receptor ...
Proton pump inhibitors (PPIs) block the gastric hydrogen potassium ATPase (H + /K + ATPase) and inhibit gastric acid secretion. These drugs have emerged as the treatment of choice for acid-related diseases, including gastroesophageal reflux disease (GERD) and peptic ulcer disease. PPIs also can bind to other types of proton pumps such as those ...
The H 2 receptor antagonists are a class of drugs used to block the action of histamine on parietal cells in the stomach, decreasing the production of acid by these cells. H 2 antagonists are used in the treatment of dyspepsia, although they have been surpassed in popularity by the more effective [1] proton pump inhibitors.
Fundic gland polyposis is a medical syndrome where the fundus and the body of the stomach develop many fundic gland polyps.The condition has been described both in patients with familial adenomatous polyposis (FAP) and attenuated variants (AFAP), and in patients in whom it occurs sporadically.
H 2 antagonists can be used in the treatment of dyspepsia, peptic ulcers and gastroesophageal reflux disease. They have been surpassed by proton pump inhibitors (PPIs). The PPI omeprazole was found to be more effective at both healing and alleviating symptoms of ulcers and reflux oesophagitis than the H 2 blockers ranitidine and cimetidine. [2]
Treatment failure may typically be attributed to antibiotic resistance, or inadequate acid suppression from proton-pump inhibitors. [150] Following clinical trials, the use of the potassium-competitive acid blocker vonoprazan , which has a greater acid suppressive action, was approved for use in the US in 2022.
Mucosal disruption in acid peptic disease patients can be caused by infection, barrier disruption, or gastric acid hypersecretion.Acid peptic diseases can arise due to various risk factors such as Helicobacter pylori infection, alcoholism, tobacco use, cocaine and amphetamine use, nonsteroidal anti-inflammatory drug use (NSAIDs), fasting, Zollinger-Ellison syndrome, angiogenesis inhibitor ...
The use of antacids or drugs that decrease gastric acid production (such as H2-receptor antagonists) or transport (such as proton pump inhibitors). A symptom of rare diseases such as mucolipidosis (type IV). A symptom of Helicobacter pylori infection which neutralizes and decreases secretion of gastric acid to aid its survival in the stomach. [4]
Ad
related to: stomach polyps caused by ppi or h2 acid reflux treatment